Literature DB >> 16373277

Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis.

Helene Lettesjö1, Tony Hansson, Christer Peterson, Kjell-Arne Ung, Gisela Ringström, Hasse Abrahamsson, Magnus Simrén.   

Abstract

OBJECTIVE: Irritable bowel syndrome (IBS) and collagenous colitis (CC) share chronically recurring symptoms of altered bowel habits associated with abdominal pain or discomfort. The aims of the present study were to investigate whether inflammatory markers could be detected in faeces from patients with IBS and CC, and to elucidate whether such analyses could be used as non-invasive tools to distinguish between these disorders.
MATERIAL AND METHODS: Stool samples were obtained from 18 patients with CC, 46 patients with IBS and 20 healthy controls (HC). Eosinophil protein X (EPX), myeloperoxidase (MPO), tryptase, interleukin-1 beta (IL-1beta) and tumour necrosis factor alpha (TNFalpha) were measured in supernatants from processed faeces using immunoassays.
RESULTS: EPX levels were enhanced in faeces from CC patients (median 3.8 microg/g (0.47-16.2)) compared to patients with IBS (0.44 microg/g (0.25-1.8)), p<0.001, and HC (0.46 microg/g (0.21-1.3)), p<0.001. In addition, MPO was increased in CC patients (11.7 microg/g (2.0-124)) compared to IBS patients (1.7 microg/g (0.81-5.2)), p<0.01, and HC (2.5 microg/g (1.1-6.3)), p<0.05. Tryptase was found in 9/18 patients with CC, 6/46 with IBS and 1/19 HC. IL-1beta was only enhanced in 2/11 CC patients and TNFalpha was not detected in any sample.
CONCLUSIONS: Increased levels of EPX, MPO and tryptase were observed in stools from collagenous colitis patients, whereas the levels in IBS patients did not differ from healthy controls. Our data suggest that faecal markers could be used as part of the clinical work-up to determine which patients should be biopsied and evaluated for collagenous colitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16373277     DOI: 10.1080/00365520510023909

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  18 in total

Review 1.  [Biomarkers for chronic inflammatory diseases].

Authors:  D Holzinger; D Föll
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

2.  Noninfectious colitides: collagenous colitis, lymphocytic colitis, diversion colitis, and chemically induced colitis.

Authors:  Amy J Thorsen
Journal:  Clin Colon Rectal Surg       Date:  2007-02

Review 3.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

4.  Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome.

Authors:  Jeroen Aerssens; Michael Camilleri; Willem Talloen; Leen Thielemans; Hinrich W H Göhlmann; Ilse Van Den Wyngaert; Theo Thielemans; Ronald De Hoogt; Christopher N Andrews; Adil E Bharucha; Paula J Carlson; Irene Busciglio; Duane D Burton; Thomas Smyrk; Raul Urrutia; Bernard Coulie
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02       Impact factor: 11.382

Review 5.  Microscopic colitis.

Authors:  Kristin E Burke; Mauro D'Amato; Siew C Ng; Darrell S Pardi; Jonas F Ludvigsson; Hamed Khalili
Journal:  Nat Rev Dis Primers       Date:  2021-06-10       Impact factor: 52.329

6.  Microscopic colitis.

Authors:  John R Stroehlein
Journal:  Curr Treat Options Gastroenterol       Date:  2007-06

7.  Lessons Learnt from Post-Infectious IBS.

Authors:  Sushil K Sarna
Journal:  Front Physiol       Date:  2011-08-23       Impact factor: 4.566

8.  European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.

Authors:  Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch
Journal:  United European Gastroenterol J       Date:  2021-02-22       Impact factor: 4.623

9.  Novel Testing Enhances Irritable Bowel Syndrome Medical Management: The IMMINENT Study.

Authors:  Kelly Parsons; Julius Goepp; Bryan Dechairo; Elizabeth Fowler; Nathan Markward; Patrick Hanaway; Teresa McBride; Darryl Landis
Journal:  Glob Adv Health Med       Date:  2014-05

10.  Frequency of abnormal fecal biomarkers in irritable bowel syndrome.

Authors:  Julius Goepp; Elizabeth Fowler; Teresa McBride; Darryl Landis
Journal:  Glob Adv Health Med       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.